CLT Contraindications & Precautions for Lymphatic Therapy 3

Question 1

A patient actively receiving chemotherapy presents for lymphedema management. The primary treatment concern is:

Accepted Answer

Increased infection risk due to chemotherapy-induced immunosuppression

Answer

Chemotherapy causes immunosuppression, so meticulously monitoring skin integrity is essential to prevent infection during CDT.

Question 2

When treating a patient with a pacemaker, the CLT must:

Accepted Answer

Avoid electrical therapeutic modalities and exercise caution with thorax MLD

Answer

Electrical modalities are contraindicated with pacemakers, and thorax MLD requires extra caution, but extremity MLD is generally safe to perform.

Question 3

For a patient with obesity and lower extremity lymphedema, the appropriate clinical approach is to:

Accepted Answer

Adapt MLD technique, bandaging, and garments to the patient's anatomy

Answer

CDT principles remain applicable for patients with obesity, but techniques, padding layers, and compression garments must be individually adapted to function properly.

Question 4

Which precaution is recommended when performing MLD in the neck and thorax region on a patient with bronchial asthma?

Accepted Answer

Monitor for respiratory distress and be prepared to modify or stop treatment

Answer

Asthma is a relative contraindication for neck/thorax MLD; treatment can proceed with close respiratory monitoring and readiness to stop if bronchospasm is triggered.

Question 5

A therapist observes a red, warm, tender streak extending from the patient's lymphedematous leg toward the groin. The correct action is:

Accepted Answer

Refer immediately to a physician as this indicates likely lymphangitis

Answer

Red streaking toward the lymph nodes (lymphangitis) indicates a serious spreading infection requiring immediate medical referral, not lymphatic therapy.

CLT - Certified Lymphatic Therapist Practice Test

CLT - Certified Lymphatic Therapist Practice Test

CLT Contraindications & Precautions for Lymphatic Therapy 3